592 related articles for article (PubMed ID: 19358815)
1. [The cannabinoid system and pain: towards new drugs?].
Beltramo M
J Soc Biol; 2009; 203(1):99-106. PubMed ID: 19358815
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.
Davis MP
Expert Opin Investig Drugs; 2014 Aug; 23(8):1123-40. PubMed ID: 24836296
[TBL] [Abstract][Full Text] [Related]
3. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms.
Beltramo M; Bernardini N; Bertorelli R; Campanella M; Nicolussi E; Fredduzzi S; Reggiani A
Eur J Neurosci; 2006 Mar; 23(6):1530-8. PubMed ID: 16553616
[TBL] [Abstract][Full Text] [Related]
4. Recent data on cannabinoids and their pharmacological implications in neuropathic pain.
Coman OA; Paunescu H; Coman L; Badarau A; Fulga I
J Med Life; 2008; 1(4):365-75. PubMed ID: 20108515
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoid type 2 receptor as a target for chronic - pain.
Beltramo M
Mini Rev Med Chem; 2009 Jan; 9(1):11-25. PubMed ID: 19149657
[TBL] [Abstract][Full Text] [Related]
6. Central and peripheral sites of action for CB₂ receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats.
Hsieh GC; Pai M; Chandran P; Hooker BA; Zhu CZ; Salyers AK; Wensink EJ; Zhan C; Carroll WA; Dart MJ; Yao BB; Honore P; Meyer MD
Br J Pharmacol; 2011 Jan; 162(2):428-40. PubMed ID: 20880025
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoid mechanisms of pain suppression.
Walker JM; Hohmann AG
Handb Exp Pharmacol; 2005; (168):509-54. PubMed ID: 16596786
[TBL] [Abstract][Full Text] [Related]
8. Histone methyltransferase G9a diminishes expression of cannabinoid CB
Luo Y; Zhang J; Chen L; Chen SR; Chen H; Zhang G; Pan HL
J Biol Chem; 2020 Mar; 295(11):3553-3562. PubMed ID: 32024693
[TBL] [Abstract][Full Text] [Related]
9. Targeting CB2 receptors and the endocannabinoid system for the treatment of pain.
Anand P; Whiteside G; Fowler CJ; Hohmann AG
Brain Res Rev; 2009 Apr; 60(1):255-66. PubMed ID: 19150370
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid 1 (CB1) receptor--pharmacology, role in pain and recent developments in emerging CB1 agonists.
Talwar R; Potluri VK
CNS Neurol Disord Drug Targets; 2011 Aug; 10(5):536-44. PubMed ID: 21631407
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoid CB
Li AL; Carey LM; Mackie K; Hohmann AG
J Pharmacol Exp Ther; 2017 Aug; 362(2):296-305. PubMed ID: 28592614
[TBL] [Abstract][Full Text] [Related]
12. The multiplicity of spinal AA-5-HT anti-nociceptive action in a rat model of neuropathic pain.
Malek N; Kostrzewa M; Makuch W; Pajak A; Kucharczyk M; Piscitelli F; Przewlocka B; Di Marzo V; Starowicz K
Pharmacol Res; 2016 Sep; 111():251-263. PubMed ID: 27326920
[TBL] [Abstract][Full Text] [Related]
13. CB1 and CB2 receptor agonists promote analgesia through synergy in a murine model of tumor pain.
Khasabova IA; Gielissen J; Chandiramani A; Harding-Rose C; Odeh DA; Simone DA; Seybold VS
Behav Pharmacol; 2011 Sep; 22(5-6):607-16. PubMed ID: 21610490
[TBL] [Abstract][Full Text] [Related]
14. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson's disease.
Han QW; Yuan YH; Chen NH
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jan; 96():109745. PubMed ID: 31442553
[TBL] [Abstract][Full Text] [Related]
16. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset.
Shoemaker JL; Seely KA; Reed RL; Crow JP; Prather PL
J Neurochem; 2007 Apr; 101(1):87-98. PubMed ID: 17241118
[TBL] [Abstract][Full Text] [Related]
17. CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.
Deng L; Cornett BL; Mackie K; Hohmann AG
Mol Pharmacol; 2015 Jul; 88(1):64-74. PubMed ID: 25904556
[TBL] [Abstract][Full Text] [Related]
18. Involvement of central and peripheral cannabinoid receptors on antinociceptive effect of tetrahydrocannabinol in muscle pain.
Bagüés A; Martín MI; Sánchez-Robles EM
Eur J Pharmacol; 2014 Dec; 745():69-75. PubMed ID: 25446925
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain.
Toth CC; Jedrzejewski NM; Ellis CL; Frey WH
Mol Pain; 2010 Mar; 6():16. PubMed ID: 20236533
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoids against pain. Efficacy and strategies to reduce psychoactivity: a clinical perspective.
Karst M; Wippermann S
Expert Opin Investig Drugs; 2009 Feb; 18(2):125-33. PubMed ID: 19236260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]